European Market Report for Uterine Fibroid Embolization Devices
|出版商||iData Research Inc.||商品編碼||371089|
|出版日期||內容資訊||英文 81 Pages
|歐洲的子宮栓塞術設備市場分析 European Market Report for Uterine Fibroid Embolization Devices|
|出版日期: 2016年09月01日||內容資訊: 英文 81 Pages||
本報告提供歐洲各國子宮栓塞術 (UFE) 設備的市場相關分析，提供您技術·產品概要，及整體市場規模的實際成果值·預測值，各產品詳細趨勢，主要的推動及阻礙市場要素，主要企業的市場佔有率，各國市場的市場結構等調查評估。
The UFE market has decreased over the past couple of years as there has been a reduction of active marketing. Moreover, UFE must compete with a wide array of procedures available to treat heavy bleeding due to uterine fibroids. These other treatments and procedures include hysterectomy, pharmacological alternatives, global endometrial ablation, endometrial resection and other minimally invasive surgical procedures. For more price-sensitive countries, such as France, Spain, Italy and Portugal, alternative treatments present significant competition as patients and physicians look for inexpensive methods for the management or treatment of uterine fibroids. Moreover, because of the economic situation, many women are delaying surgical treatments.
Uterine fibroid embolization (UFE), also known as uterine artery embolization (UAE) is a radiology treatment for fibroids. Fibroids, also known as myomas, are masses of muscle tissue and fiber located on the wall of the uterus that can cause heavy bleeding and pain. Fibroids depend on the uterine arteries for nourishment, and they take significant blood supply from these vessels. UFE restricts blood flow to fibroids, causing them to shrink significantly. This procedure does not involve general anesthesia and is appropriate for women who want an alternative to a myomectomy, also known as fibroidectomy. It is a much less invasive way to treat fibroids than a hysterectomy, has a much shorter recovery time and leaves almost no scarring. The effects of UFE on fertility are being researched; some results suggest that fertility after UFE is comparable to fertility after myomectomy.